Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Detalhes bibliográficos
Main Authors:	Mueller, G, Vanderkerken, K, Russell, R, Croucher, P
Formato:	Conference item
Publicado em:	2004

Registos relacionados

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
Por: Mueller, G, et al.
Publicado em: (2004)

The Role of Myeloma Cells to Osteoclast Activation
Por: Bahare Sadeghi, et al.
Publicado em: (2010-01-01)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
Por: Ersek, A, et al.
Publicado em: (2015)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Por: Shipman, C, et al.
Publicado em: (2000)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Por: Edwards, C, et al.
Publicado em: (2007)

An In Vitro Model of Murine Osteoclast-Mediated Bone Resorption
Por: Xiaoyue Sun, et al.
Publicado em: (2024-11-01)

Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
Por: Leng, H
Publicado em: (2019)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Por: Croucher, P, et al.
Publicado em: (2002)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
Por: Mabilleau, G, et al.
Publicado em: (2009)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
Por: Mabilleau, G, et al.
Publicado em: (2009)

Osteoprotegerin and the development of myeloma bone disease
Por: Croucher, P, et al.
Publicado em: (2004)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
Por: Zhuang, J, et al.
Publicado em: (2008)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Por: Dongzheng Gai, et al.
Publicado em: (2022-09-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Por: Yu-Tzu Tai, et al.
Publicado em: (2018-08-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
Por: Tibullo eDaniele, et al.
Publicado em: (2015-10-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
Por: Shipman, C, et al.
Publicado em: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Por: Croucher, P, et al.
Publicado em: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
Por: Shipman, C, et al.
Publicado em: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Por: Croucher, P, et al.
Publicado em: (2003)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
Por: Jing Fu, et al.
Publicado em: (2023-07-01)

TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
Por: Hua Bai, et al.
Publicado em: (2018-10-01)

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO
Por: Mabilleau, G, et al.
Publicado em: (2010)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Por: Vanderkerken, K, et al.
Publicado em: (2003)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
Por: Zhuang, J, et al.
Publicado em: (2007)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
Por: Zhuang, J, et al.
Publicado em: (2012)

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids
Por: Xu, K, et al.
Publicado em: (2009)

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
Por: Minna Qiao, et al.
Publicado em: (2015-01-01)

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
Por: Maiko Matsushita, et al.
Publicado em: (2015-01-01)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
Por: Junling Zhuang, et al.
Publicado em: (2012-01-01)

In vitro generation of mature human osteoclasts.
Por: Hemingway, F, et al.
Publicado em: (2011)

In vitro generation of mature human osteoclasts.
Por: Hemingway, F, et al.
Publicado em: (2011)

Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
Por: Kudo, O, et al.
Publicado em: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
Por: Liesbeth Bieghs, et al.
Publicado em: (2010-01-01)

Effect of amorphous silica nanoparticles on <it>in vitro </it>RANKL-induced osteoclast differentiation in murine macrophages
Por: Nagano Kazuya, et al.
Publicado em: (2011-01-01)

Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice.
Por: Matilda H-C Sheng, et al.
Publicado em: (2012-01-01)

Osteoclasts and Microgravity
Por: John Kelly Smith
Publicado em: (2020-09-01)

Estrogen receptor gene expression in osteoclasts loss with osteoclast maturation.
Por: Oreffo, R, et al.
Publicado em: (1997)

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts
Por: Zhao W, et al.
Publicado em: (2025-03-01)

NK cells support osteoclast formation in vitro
Por: Owen, S, et al.
Publicado em: (2004)

Activated T lymphocytes support osteoclast formation in vitro.
Por: Horwood, N, et al.
Publicado em: (1999)